The proposed addendum to the International Conference on Harmonization document, Statistical Principles for Clinical Trials, can be read in two ways. There is a new framework for talking about estimands, but is it about fitting present methods into the framework? Or is it about changing methods? My answer: some of each. Where different methods are needed, there are challenging problems in estimating some desirable estimands, but there may also be desirable estimands that can be estimated easily and robustly.
MehrotraDV. A note on the draft ICH guidance on estimands and sensitivity analysis. Clin Trials2019; 16(4): 339–344.
4.
HollisSCampbellF.What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ1999; 319(7211): 670–674.
5.
LeuchsAKBrandtAZinserlingJ, et al. Disentangling estimands and the intention-to-treat principle. Pharm Stat2017; 16(1): 12–19.
6.
O’NeillRTempleR.The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clin Pharmacol Ther2012; 91(3): 550–554.
7.
National Research Council. The prevention and treatment of missing data in clinical trials. Washington, DC: National Academies Press, 2010.
8.
AkachaMBretzFRubergS.Estimands in clinical trials – broadening the perspective. Stat Med2017; 36: 5–19.
9.
RobinsJRichardsonTSpirtesP.On identification and inference for direct effects. Report no. 563, 26November2009. Seattle, WA: Department of Statistics, University of Washington.
10.
HubbardAEJewellNPvan der LaanMJ. Direct effects and effects among the treated. In: van der LaanMJ (ed.) Targeted learning: causal inference for observational and experimental data. New York: Springer, 2011, pp.133–143.
11.
PermuttT.Effects in adherent subjects. Stat Biopharm Res2018; 10: 233–235.
12.
PermuttTLiF.Trimmed means for symptom trials with dropouts. Pharm Stat2017; 16(1): 20–28.
13.
PermuttTHebelJR.Simultaneous-equation estimation in a clinical trial of the effect of smoking on birth weight. Biometrics1989; 45(2): 619–622.
14.
GouldAL.A new approach to the analysis of clinical drug trials with withdrawals. Biometrics1980; 36(4): 721–727.
